Researchers of a study suggest that immune checkpoint inhibitor–based therapy is equally effective for both Black and White patients with metastatic renal cell carcinoma. This research is particularly significant, as racial factors often influence treatment recommendations in cancer care. The study involved a retrospective review of 2,592 patients with metastatic renal cell carcinoma who received either immune checkpoint inhibitor–based therapy or sunitinib as their first line of treatment. Researchers found that approximately 92% of the participants were White, with around 56% of patients from both racial groups receiving immune checkpoint inhibitor–based therapy.
The results showed that both Black and White patients who were treated with immune checkpoint inhibitors experienced better progression-free survival compared with those who received sunitinib. Furthermore, when adjusting for comparisons between Black and White patients across the entire cohort, there were no significant differences in treatment outcomes. These findings suggest that immune checkpoint inhibitor–based therapy should be considered a viable treatment option for both Black and White patients with metastatic renal cell carcinoma.
Reference: The ASCO Post Staff. Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma. The ASCO Post. Updated January 30, 2024. Accessed March 5, 2024. https://ascopost.com/news/january-2024/immune-checkpoint-inhibitor-based-therapy-may-have-comparative-efficacy-in-black-and-white-patients-with-metastatic-renal-cell-carcinoma/
